Autoinjector preference among patients with multiple sclerosis: results from a national survey

References

• BayasAImproving adherence to injectable disease-modifying drugs in multiple sclerosisExpert Opin Drug Deliv201310328528723339371
   PubMed Web of Science ®Google Scholar
• LugaresiARottoliMRPattiFFostering adherence to injectable disease-modifying therapies in multiple sclerosisExpert Rev Neurother20141491029104225109614
   PubMed Web of Science ®Google Scholar
• TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
   PubMed Web of Science ®Google Scholar
• WingerchukDMCarterJLMultiple sclerosis: current and emerging disease-modifying therapies and treatment strategiesMayo Clin Proc201489222524024485135
   PubMed Web of Science ®Google Scholar
• BayasAJappGFuldaUKallmannBAInjection devices in MS therapy: survey on neurologists, MS-nurses and patientsNervenheilkunde2010295762
   Google Scholar
• D’ArcyCThomasDStonemanDParkesLPatient assessment of an electronic device for subcutaneous self-injection of interferon beta-1a for multiple sclerosis: an observational study in the UK and IrelandPatient Prefer Adherence20126556122298944
   PubMed Web of Science ®Google Scholar
• de SaJUrbanoGReisLAssessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosisCurr Med Res Opin20102692237224220687777
   PubMed Web of Science ®Google Scholar
• DevonshireVArbizuTBorreBPatient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurol2010102820433746
   PubMed Web of Science ®Google Scholar
• PhillipsJTFoxEGraingerWTuccilloDLiuSDeykinAAn open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjectsBMC Neurol20111112621999176
   PubMed Web of Science ®Google Scholar
• Verdun di CantognoERussellSSnowTUnderstanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practicesPatient Prefer Adherence2011517318021573048
   PubMed Web of Science ®Google Scholar
• BrochetBLemaireGBeddiafAet l’Epicure Study GRéduction des réactions cutanées aux points d’injection avec deux auto-injecteurs chez des patients ayant une sclérose en plaques rémittente débutant un traitement par interféron bêta-1b : étude randomisée en cross-over. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices]Rev Neurol (Paris)20061626–7735740 French16840982
   PubMed Web of Science ®Google Scholar
• PozzilliCSchweikertBEcariUOentrichWBetaPlus Study groupSupportive strategies to improve adherence to IFN beta-1b in multiple sclerosis – results of the betaPlus observational cohort studyJ Neurol Sci20113071–212012621636099
   PubMed Web of Science ®Google Scholar
• BayasAOualletJCKallmannBAdherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART studyExpert Opin Drug Deliv20151281239125026098143
   PubMed Web of Science ®Google Scholar
• WellerISaakeASchreinerTVogelreuterJPetroffNPatient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1bPatient Prefer Adherence2015995195926185425
   PubMed Web of Science ®Google Scholar
• BaroneDASingerBAMerkovLRamettaMSuarezGSurvey of US patients with multiple sclerosis: comparison of the new electronic interferon beta-1b autoinjector (BETACONNECT™) with mechanical autoinjectorsNeurol Ther20165215516727277705
   PubMed Web of Science ®Google Scholar
• ZiemssenTSylvesterLRamettaMRossAPPatient satisfaction with the new interferon beta-1b autoinjector (BETACONNECT™)Neurol Ther20154212513626662362
   PubMedGoogle Scholar
• SingerBWraySMillerTPatient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosisMult Scler Relat Disord201212879425876936
   PubMed Web of Science ®Google Scholar
• HuppertsRBeckerVFriedrichJMultiple sclerosis patients treated with intramuscular IFN-beta-1a autoinjector in a real-world set-ting: prospective evaluation of treatment persistence, adherence, quality of life and satisfactionExpert Opin Drug Deliv2015121152525430947
   PubMed Web of Science ®Google Scholar
• ThakurKManuelLTomlinsonMAutoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort® devicesPragmat Obs Res20134192627774021
   PubMedGoogle Scholar
• WHOAdherence to long-term therapies – Evidence for actionGenevaWorld Health Organization2003
   Google Scholar
• PozzilliCSchweikertBEcariUOentrichWBuggeJPQuality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus studyJ Neurol2012259112319232822527232
   PubMed Web of Science ®Google Scholar
• KohlmannTWangCLipinskiJThe impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health statusJ Neurosci Nurs2013453E3E14
   Web of Science ®Google Scholar
• ZettlUKBauer-SteinhusenUGlaserTAdherence to long-term interferon beta-1b injection therapy in patients with multiple sclerosis using an electronic diaryAdv Ther201633583484727090116
   PubMed Web of Science ®Google Scholar
• AssoulineSBuccheriVDelmerAPharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemiaBr J Clin Pharmacol20158051001100925900065
   PubMed Web of Science ®Google Scholar
• ShpilbergOJackischCSubcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidaseBr J Cancer201310961556156124002601
   PubMed Web of Science ®Google Scholar